Dognosis, the deep-tech company digitizing and scaling canine olfactory intelligence for healthcare, has been selected for the inaugural Accel Atoms X cohort, a LeapTech programme backed by Accel India and Prosus that supports mission-driven founders building at the intersection of science and engineering.

‍

Atoms X is Accel's most selective early-stage track, backing six companies in its inaugural cohort. The programme combines Accel's global network with Prosus's expertise in scaling technology across emerging markets, providing capital, mentorship, and long-term company-building support.

‍

Dogs have detected cancer and other diseases in over 50 peer-reviewed studies across 28+ conditions, consistently outperforming the machines built to replace them. The bottleneck was never the dog. It was the human-canine interface: a handler watching a dog sit or bark, then making a subjective call. Dognosis trained AI to read dogs directly, decoding brain waves and body language through a patented brain-computer interface and multi-modal sensing platform. The result is BreathEasy, a non-invasive multi-cancer screening test that brings the diagnostic power of a full-body scan to a five-minute breath sample, collected anywhere from a screening camp to a patient's home.

‍

"For 11,000 years we have had access to superhuman olfactory intelligence, constrained by a primitive interface. Dognosis is building the bridge between what dogs can perceive and what medicine can act on. The backing of Accel and Prosus through Atoms X is a signal that the world is ready for this leap," said Akash Kulgod, Co-Founder and CEO, Dognosis.

‍

With 10+ active hospital pilots across India and technology validated with the Government of Singapore, Dognosis is turning the world's most sensitive biological detection system into a new paradigm for how humanity detects disease.

‍

About Dognosis

Dognosis leverages brain-computer interfaces, robotics, and machine learning to digitise and scale the canine sense of smell. Founded in 2024 and headquartered in Bengaluru, the company is backed by Boost VC, 1517 Fund, Accel India, MBX Capital, House Fund, Caffeinated Capital, Arben Ventures, PurposeTech, and the Neta Foundation. For more information, visit dognosis.tech.